![ALIGOS THERAPEUTICSCS INC](https://cdn.moneypeak.ai/logos/US01626L1052.png)
US01626L1052 - ALGS - A2QCEK (XNAS)
ALIGOS THERAPEUTICSCS INC Acción
39,86 USD
Cotizaciones actuales de ALIGOS THERAPEUTICSCS INC
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria | Variación diaria % |
---|---|---|---|---|---|---|
![]() NASDAQ |
ALGS
|
USD
|
23.12.2024 16:16
|
39,86 USD
| 39,52 USD | 0,86 % |
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
-1,19 % | 16,58 % | 96,26 % | 328,14 % | 253,53 % | 127,77 % | -89,26 % |
Perfil de la empresa para ALIGOS THERAPEUTICSCS INC Acción
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Datos de la empresa para ALIGOS THERAPEUTICSCS INC Acción
![ALIGOS THERAPEUTICSCS INC](https://cdn.moneypeak.ai/logos/US01626L1052.png)
Nombre ALIGOS THERAPEUTICSCS INC
Empresa Aligos Therapeutics, Inc.
Símbolo ALGS
Sitio web https://www.aligos.com
Mercado principal
NASDAQ
![XNAS](https://cdn.moneypeak.ai/mic/XNAS.png)
WKN A2QCEK
ISIN US01626L1052
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Lawrence M. Blatt MBA, Ph.D.
Capitalización de mercado 56 Mio
País Estados Unidos de América
Moneda USD
Empleados 0,1 T
Dirección One Corporate Drive, 94080 South San Francisco
Fecha de OPV 2020-10-16
Splits de acciones
Fecha | Split |
---|---|
19.08.2024 | 1:25 |
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | 5WK.F |
NASDAQ | ALGS |
Otras acciones
Los inversores que tienen ALIGOS THERAPEUTICSCS INC también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.